Emerald Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

Emerald Advisers’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-5,494	Closed	-$689K	–	379
2015 Q1	$689K	Sell	5,494 -119	-2%	-$14.3K	0.03%	267
2014 Q4	$667K	Sell	5,613 -50	-0.9%	-$5.63K	0.04%	263
2014 Q3	$636K	Sell	5,663 -8,009	-59%	-$763K	0.04%	267
2014 Q2	$1.29M	Buy	+13,672	New	+$959K	0.07%	237
2014 Q1	–	Sell	-22,326	Closed	-$1.66M	–	376
2013 Q4	$1.66M	Sell	22,326 -12,984	-37%	-$904K	0.09%	215
2013 Q3	$2.68M	Sell	35,310 -377	-1%	-$30K	0.15%	164
2013 Q2	$2.86M	Buy	+35,687	New	+$2.63M	0.17%	158

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Emerald Advisers's VRTX Position: Q2 2015 in Review

Emerald Advisers sold out of Vertex Pharmaceuticals (VRTX) in Q2 2015, closing a stake of 5,494 shares — an estimated $689K sold.

Emerald Advisers first reported a position in VRTX in Q2 2013 and held it in 7 quarters. The position peaked at $2.86M in Q2 2013. 501 funds tracked by Wall St. Rank hold VRTX as of Q2 2015.

Emerald Advisers reported no remaining Vertex Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Emerald Advisers sold 5,494 Vertex Pharmaceuticals shares in Q2 2015, an estimated $689K.
Emerald Advisers first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Emerald Advisers's Vertex Pharmaceuticals position peaked at $2.86M in Q2 2013.
501 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2015.

Based on Emerald Advisers's 13F filing for Q2 2015, filed 28 Jul 2015.